NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting
- Written by ACN Newswire
 |
Illustration: 3D reconstruction of CT scan (tumor in yellow) patient treated at a 15% dose level showing a Complete Response 7 months after the end of the treatment. |
 |
Best Response obtained for patients at different dose levels (*patient one non evaluable) |
 |